NurExone Biologic Inc. (TSX.V: NRX) (OTCQB: NRXBF) (FSE: J90) has received first place in the Healthcare category at the BOLD Awards VII Gala, held March 27, 2026, in Barcelona. The award recognizes the company's leadership in developing exosome-based therapies for central nervous system (CNS) injuries. The BOLD Awards, judged by a panel of global industry leaders, honor bold and innovative companies across various sectors. This recognition highlights NurExone's pioneering approach in regenerative medicine.
In conjunction with the award, the company provided a corporate update, announcing plans to engage Investor Brand Network (IBN), subject to TSX Venture Exchange approval. The engagement, effective April 1, 2026, is designed to support investor awareness efforts through the distribution of news and updates across more than 5,000 outlets. Under a one-year agreement with a monthly fee of $6,500, the partnership aims to strengthen market visibility and foster long-term shareholder value. This strategic move comes as NurExone advances its lead product, ExoPTEN, which has demonstrated strong preclinical data supporting its potential in treating acute spinal cord and optic nerve injuries.
The company's regulatory milestones, including obtaining Orphan Drug Designation, facilitate its roadmap towards clinical trials in the United States and Europe. Commercially, NurExone is expected to offer solutions to companies interested in quality exosomes and minimally invasive targeted delivery systems for other indications. The company has also established Exo-Top, a U.S. subsidiary, to anchor its North American activity and growth strategy.
The BOLD Awards win and the engagement with IBN underscore NurExone's commitment to advancing its pipeline and enhancing its corporate profile. For more information, visit the company's website at https://nurexone.com/. The full press release is available at https://ibn.fm/cWtqT.
